Table 2.

ADCC Activity of Various Effector Cells in Myeloma Patients

Source of Effector CellsCD16+ Cells (%) ADCC Activity (%)
Medium IL-2– Stimulated
PBMCs  12 ± 6 30 ± 9  45 ± 9* 
BMMCs  7 ± 5  17 ± 20 31 ± 12  
PBSC collections  29 ± 6 21 ± 9 36 ± 10* 
Source of Effector CellsCD16+ Cells (%) ADCC Activity (%)
Medium IL-2– Stimulated
PBMCs  12 ± 6 30 ± 9  45 ± 9* 
BMMCs  7 ± 5  17 ± 20 31 ± 12  
PBSC collections  29 ± 6 21 ± 9 36 ± 10* 

PBMCs and BMMCs were obtained from five myeloma patients before PBSC harvest. Effector cells were cultured alone or with IL-2 (500 U/mL) for 3 days, then tested for ADCC activity against RPMI 8226 cells at an E/T ratio of 50 in the presence of humanized anti-HM1.24 MoAb (1 μg/mL). Results are expressed as the mean ± SD.

*

P < .05, compared with the data of nonactivated effector cells.

P < .005, compared with the percentage of PBMCs.

or Create an Account

Close Modal
Close Modal